for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Albireo Pharma Inc

ALBO.OQ

Latest Trade

18.24USD

Change

-0.10(-0.55%)

Volume

8,024

Today's Range

18.19

 - 

18.56

52 Week Range

16.26

 - 

38.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Albireo Q3 Loss Per Share $1.73

Nov 6 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $1.73.Q3 REVENUE $1.4 MILLION VERSUS $200,000.Q3 REVENUE ESTIMATE $959,000 -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-1.56 -- REFINITIV IBES DATA.ALBIREO PHARMA - FOR FY 2019, ANTICIPATES TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE IN RANGE OF $70 MILLION-$75 MILLION.CONTINUES TO ANTICIPATE THAT CURRENT CASH BALANCE WILL BE SUFFICIENT TO MEET OPERATING NEEDS INTO 2021.

Albireo Pharma Q2 Loss Per Share $1.35

Aug 8 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.35.Q2 REVENUE $1.3 MILLION VERSUS $700,000.Q2 REVENUE ESTIMATE $767,000 -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-1.43 -- REFINITIV IBES DATA.ODEVIXIBAT PHASE 3 PEDFIC 1 TOPLINE RESULTS EXPECTED MID-2020.COMPANY HAD CASH AND CASH EQUIVALENTS AT JUNE 30, 2019, OF $157.7 MILLION.ANTICIPATES ITS CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET ITS OPERATING NEEDS INTO 2021.

Albireo Provides Mid-Year Clinical Development Update

July 9 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO PROVIDES MID-YEAR CLINICAL DEVELOPMENT UPDATE.ALBIREO PHARMA INC - EXPECTS ODEVIXIBAT PEDFIC 1 PHASE 3 TOPLINE DATA MID-2020 -.ALBIREO PHARMA INC - SITE ACTIVATED FOR ODEVIXIBAT PEDFIC 2 EXPANDED OPEN-LABEL COHORT.ALBIREO PHARMA INC - ODEVIXIBAT BILIARY ATRESIA PIVOTAL TRIAL EXPECTED TO BEGIN IN 2020.ALBIREO PHARMA INC - MOVES INTO NASH WITH INITIATION OF ELOBIXIBAT PHASE 2 TRIAL.ALBIREO PHARMA INC - ENCOURAGED WITH RECRUITING EFFORTS BY PARTICIPATING SITES IN OUR PHASE 3 TRIAL FOR ODEVIXIBAT IN PFIC.

Albireo Pharma Reports Q1 Loss Per Share Of $1.39

May 9 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $1.39.Q1 REVENUE $570,000 VERSUS $11.2 MILLION.Q1 REVENUE ESTIMATE $974,000 -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-1.32 -- REFINITIV IBES DATA.FOR FY 2019, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE IN RANGE OF $75-$80 MILLION.ANTICIPATE CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OUR OPERATING NEEDS INTO 2021.

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat

April 11 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO ANNOUNCES FDA CLEARANCE OF IND TO COMMENCE PHASE 2 TRIAL OF ELOBIXIBAT FOR THE TREATMENT OF NAFLD/NASH.ALBIREO ANNOUNCES FDA CLEARANCE OF IND TO COMMENCE PHASE 2 TRIAL OF ELOBIXIBAT FOR THE TREATMENT OF NAFLD/NASH.ALBIREO PHARMA INC - INITIATION OF PHASE 2 CLINICAL TRIAL EXPECTED IN Q2 2019.ALBIREO PHARMA INC - - IBAT INHIBITION HAS POTENTIAL TO IMPACT KEY MARKERS OF NASH -.ALBIREO PHARMA INC - STUDY SHOULD BE INITIATED IN Q2 OF 2019, WITH RESULTS PLANNED FOR MID-2020.

Albireo Expects Current Cash Balance To Be Sufficient To Meet Operating Needs Into 2021

March 7 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO REPORTS YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE.ALBIREO PHARMA INC - A4250 PHASE 3 PFIC PIVOTAL PROGRAM ON TARGET FOR END OF '19/EARLY '20 TOPLINE READOUT.ALBIREO PHARMA INC - HAD CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 OF $163.9 MILLION, COMPARED TO $53.2 MILLION AT DECEMBER 31, 2017..ALBIREO PHARMA INC - FOR FULL YEAR 2019, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE IN RANGE OF $75-$80 MILLION.ALBIREO PHARMA INC - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OUR OPERATING NEEDS INTO 2021..

Albireo Pharma Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing

March 6 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO PHARMA INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.

Albireo Granted Orphan Drug Designation By FDA For Lead Product Candidate A4250 For Treatment Of Biliary Atresia

Jan 22 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA INC - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES THIS YEAR.

Albireo Pharma Granted Orphan Designation By European Commission

Dec 18 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO GRANTED ORPHAN DESIGNATION BY EUROPEAN COMMISSION FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES IN 2019.ALBIREO PHARMA - ORPHAN DESIGNATION PROVIDES 10 YEARS MARKET EXCLUSIVITY UPON APPROVAL PLUS 2 YEARS UPON COMPLETION OF PEDIATRIC INVESTIGATION PLAN.

Albireo Q3 Loss Per Share $1.17

Nov 13 (Reuters) - Albireo Pharma Inc <ALBO.O>::ALBIREO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.17.Q3 REVENUE $237,000.Q3 REVENUE VIEW $892,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.ODEVIXIBAT SELECTED AS INTERNATIONAL NONPROPRIETARY NAME (INN) FOR A4250.A4250 GRANTED FAST TRACK AND ADDITIONAL ORPHAN DRUG DESIGNATIONS.A4250 PHASE 3 TRIAL PROGRESSING AS PLANNED, NEW NATURAL HISTORY DATA PRESENTED AT AASLD.ALBIREO PHARMA - HAD CASH AND CASH EQUIVALENTS AT SEPT 30, 2018 OF $173.6 MILLION, COMPARED TO $53.2 MILLION AT DEC 31, 2017.ALBIREO PHARMA - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OPERATING NEEDS INTO 2021.ALBIREO PHARMA - FOR FY 2018, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE AT HIGH END OF RANGE OF $45 MILLION -$50 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up